Stedesa eslicarbazepine acetate regulatory update

Sepracor submitted an NDS to Health Canada for Stedesa eslicarbazepine acetate as adjunctive therapy to treat partial-onset seizures in adults with epilepsy. An NDA for the sodium channel antagonist i...